Developer docs
API playgroundTry for free, no card

Search company profiles

InduPro

Full company profile

uuid0000pff

Namestring
InduPro
Legal namestring
InduPro, Inc.
Websiteurl
induprotx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

InduPro is a privately held, preclinical-to-early-clinical-stage biotechnology company founded in 2022 and headquartered in Seattle, WA, with a second office in Cambridge, MA. The company develops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat cancer and autoimmune/inflammatory diseases. It was co-founded by three former Merck scientists who co-invented the photocatalytic proximity labeling technology at the Merck Exploratory Science Center that underpins the platform.

InduPro's integrated platform consists of three modules: MInt (Membrane Interactomics), an AI/ML-enabled proprietary knowledge base that catalogs inherently proximal surface proteins using deep learning analysis of membrane proteomic data and identifies novel targets and co-target pairs; ARRIS (Proximity Modalities), a multi-specific antibody platform that uses induced proximity to bring cell-surface proteins into therapeutic configurations; and Therapeutic Engineering (TE), which provides internal antibody discovery, protein characterization, and optimization. The proprietary TAPA discovery engine identifies tumor-associated proximity antigens enabling selective co-targeting of tumor cells. The pipeline comprises oncology bispecific ADCs (IDP-001 co-targeting EGFR and TAPA-E1, IND filing planned Q1 2026; IDP-012 with topoisomerase 1 inhibitor payload; IDP-004 targeting MET and TAPA-M1), a PD-1 antagonist (IDP-002), and a PD-1 agonist (IDP-003) partnered with Sanofi for autoimmune indications.

InduPro is pre-revenue and operates a partnership-driven enterprise business model. The company secures strategic equity investments, R&D funding, milestone payments, and royalties through multi-program licensing deals with major pharmaceutical partners. In June 2024 it closed an $85 million Series A co-led by The Column Group and Vida Ventures. In December 2025 it announced a strategic equity investment and research collaboration with Sanofi for the bispecific PD-1 agonist program. In January 2026 it entered a global strategic collaboration with Eli Lilly covering up to three targets for total deal value of up to approximately $950 million. CEO Prakash Raman, Ph.D., joined in April 2024 from Ribon Therapeutics, with additional leadership across CSO/President Scott Lesley, Ph.D. (former Merck VP of Discovery Biologics), CMO Amanda J. Redig, M.D., Ph.D., and VPs spanning biology, chemical sciences, platform technology, biologics, operations, finance, and corporate development.

Short descriptiontext

InduPro is a Seattle-based private biotechnology company developing proximity-based protein therapeutics that modulate cell-surface protein interactions to treat cancer and autoimmune diseases, using an AI/ML-enabled membrane interactomics platform to identify novel targets and co-target pairs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
proximity-based therapeutics, bispecific antibody engineering, membrane interactomics platform, antibody drug conjugates, protein interaction modulators
Industry2 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotechnology Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Strategic Collaboration & Licensing Fees
TypeLicensing Royalties
Description

Multi-year, multi-program licensing deals with global pharma partners (Eli Lilly up to ~$950M total deal value across up to three targets; Sanofi for bispecific PD-1 agonist), typically structured with upfront payments, R&D funding, milestone payments tied to development/regulatory/commercial events, and potential royalties on commercialized products.

induprotx.com
2Pharma-Funded Preclinical/IND-Enabling Research
TypeProfessional Services
Description

Research funding from pharma partners (e.g., Sanofi funding preclinical and IND-enabling research activities on the PD-1 agonist program) for collaborative R&D execution.

induprotx.com
3Venture Equity Financing
TypeSubscription Recurring
Description

Pre-revenue company; primarily funded to date by venture equity ($85M Series A in 2024 plus additional equity investments from strategic partners Sanofi and Eli Lilly) used to advance pipeline and platform. Not operating revenue but primary capital inflow prior to licensing income.

webrazzi.com
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Eli Lilly collaboration: total deal value up to approximately $950 million across up to three targets, including equity investment, plus potential royalties (terms not fully disclosed)
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

Total deal value up to ~$950M for up to three targets; includes equity investment, upfront, R&D funding, development/regulatory milestones, and royalties; specific per-program breakdown not publicly disclosed.

induprotx.com
2Sanofi collaboration: equity investment (undisclosed) plus research funding for preclinical/IND-enabling activities; right of first negotiation for the bispecific PD-1 agonist program
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

Financial terms largely undisclosed; includes Sanofi-funded preclinical/IND-enabling research and undisclosed equity investment; future milestones/royalties not disclosed.

induprotx.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

InduPro develops proximity-based protein therapeutics that leverage inherent and induced cell-surface protein proximity to treat cancer and autoimmune diseases. The company operates a proprietary induced-proximity drug discovery platform (MInt, ARRIS and Therapeutic Engineering) and advances a pipeline of first- and best-in-class bispecific antibody candidates, including antibody-drug conjugates (ADCs), T-cell engagers, and PD-1 modulators, which it licenses to large pharmaceutical partners via multi-year strategic collaboration deals.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

InduPro offers a single, unified induced-proximity drug discovery platform composed of three core platform modules — MInt (Membrane Interactomics), ARRIS (Proximity Modalities), and Therapeutic Engineering (TE) — that work together end-to-end: MInt catalogs inherent cell-surface protein proximity via AI/ML to identify novel targets and co-target pairs; ARRIS uses multi-specific antibody technology to design induced-proximity therapeutics against those targets; and Therapeutic Engineering provides the in-house antibody discovery, protein characterization, and optimization capabilities that translate those designs into clinical molecules. The platform fuels InduPro's pipeline of first- and best-in-class bispecific candidates, including oncology programs IDP-001 (EGFR x TAPA-E1 bispecific ADC), IDP-012 (EGFR x TAPA-E1 bispecific ADC with topoisomerase 1 inhibitor payload), IDP-004 (MET x TAPA-M1 bispecific ADC), the immuno-oncology program IDP-002 (PD1 antagonist), and the autoimmune program IDP-003 (PD1 agonist, partnered with Sanofi).

Product and service5 records
1IDP-001
CategoryClinical pipeline program (oncology)
Description

First-in-class, proximity-based bispecific antibody-drug conjugate (ADC) co-targeting EGFR and a novel tumor-associated proximity antigen (TAPA-E1) for oncology; IND filing planned for Q1 2026.

2IDP-012
CategoryClinical pipeline program (oncology)
Description

Bispecific ADC with a topoisomerase 1 inhibitor payload co-targeting EGFR and TAPA-E1 in oncology.

3IDP-004
CategoryClinical pipeline program (oncology)
Description

Bispecific ADC co-targeting MET and a novel tumor-associated proximity antigen (TAPA-M1) in oncology.

4IDP-002
CategoryClinical pipeline program (immuno-oncology)
Description

Best-in-class bispecific PD-1 antagonist (PD1 x T-Cell Antigen 1) offering superior receptor occupancy through cooperative binding, independent of VEGF; enhances T-cell signaling while limiting Treg co-activation.

5IDP-003
CategoryClinical pipeline program (autoimmune)
Description

Differentiated bispecific PD-1 agonist (PD1 x T-Cell Antigen 2) that recruits PD1 into the immune synapse via a non-depleting, FcR-independent mechanism; partnered with Sanofi for autoimmune and inflammatory disorders.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Preclinical/early-clinical biotech developing induced-proximity therapeutics, including small-molecule CBL-B inhibitors, sharing InduPro's core concept of leveraging induced proximity for therapeutic effect. Comparable in stage, mechanism philosophy, and partnership-driven business model.

TypeDirect peer
Description

Oncology biotech founded by scientists from the same academic/biopharma network as InduPro's founders and leadership. Ribon's CEO and CFO (Prakash Raman and Jeff Palmer) previously held leadership roles at Ribon before joining InduPro, making it a closely comparable oncology-focused private biotech.

TypeBroad incumbent
Description

Clinical-stage leader in targeted protein degradation (PROTACs), a related induced-proximity modality that uses bifunctional small molecules rather than antibodies. Comparable as an induced-proximity platform company but at significantly more advanced clinical stage and larger scale.

TypeBroad incumbent
Description

Clinical-stage biotech developing heterobifunctional degraders (induced proximity via small molecules). Comparable platform philosophy and oncology/immunology focus, though at a more advanced clinical stage and with public-company scale and capital.

TypeBroad incumbent
Description

Public biotech with a leading bispecific antibody platform (DuoBody) and approved assets including epcoritamab. Directly comparable in bispecific antibody technology and oncology/autoimmune focus, but operates as a broad incumbent across multiple platforms and programs rather than a single-platform specialist.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing tumor-selective bispecifics and cytokines. Comparable in stage and size, with shared leadership pedigree (Ertan Eryilmaz was previously VP of Biologics at Xilio before joining InduPro) and similar focus on selective tumor targeting.

TypeDirect peer
Description

Biotech developing engineered protein therapeutics for autoimmune and inflammatory diseases using directed evolution and Fc-engineering. Comparable in autoimmune/immuno-oncology focus and bispecific modality, with overlapping leadership background (Pam Holland was previously SVP of Research at Alpine).

TypeDirect peer
Description

Clinical-stage biotech developing T cell engager (TCE) bispecifics for oncology, directly overlapping with InduPro's TAPA-based TCE programs. Comparable in modality (bispecifics), indication focus (oncology), and partnership-driven strategy.

TypeDirect peer
Description

Clinical-stage oncology company developing a diversified pipeline of targeted therapies including bispecifics. Comparable as a private/early-public oncology biotech at similar stage and scale pursuing selective tumor-targeting approaches.

10Surface Oncology
TypeDirect peer
Description

Immuno-oncology biotech developing therapeutics targeting the tumor microenvironment. Comparable in indication focus (oncology), modality (antibody-based biologics), and team pedigree (Pam Holland was previously VP of Cancer Biology at Surface).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InduPro

Biotechnology Therapeuticsinduprotx.com

InduPro is a Seattle-based private biotechnology company developing proximity-based protein therapeutics that modulate cell-surface protein interactions to treat cancer and autoimmune diseases, using an AI/ML-enabled membrane interactomics platform to identify novel targets and co-target pairs.

What InduPro does

InduPro is a privately held, preclinical-to-early-clinical-stage biotechnology company founded in 2022 and headquartered in Seattle, WA, with a second office in Cambridge, MA. The company develops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat cancer and autoimmune/inflammatory diseases. It was co-founded by three former Merck scientists who co-invented the photocatalytic proximity labeling technology at the Merck Exploratory Science Center that underpins the platform.

InduPro's integrated platform consists of three modules: MInt (Membrane Interactomics), an AI/ML-enabled proprietary knowledge base that catalogs inherently proximal surface proteins using deep learning analysis of membrane proteomic data and identifies novel targets and co-target pairs; ARRIS (Proximity Modalities), a multi-specific antibody platform that uses induced proximity to bring cell-surface proteins into therapeutic configurations; and Therapeutic Engineering (TE), which provides internal antibody discovery, protein characterization, and optimization. The proprietary TAPA discovery engine identifies tumor-associated proximity antigens enabling selective co-targeting of tumor cells. The pipeline comprises oncology bispecific ADCs (IDP-001 co-targeting EGFR and TAPA-E1, IND filing planned Q1 2026; IDP-012 with topoisomerase 1 inhibitor payload; IDP-004 targeting MET and TAPA-M1), a PD-1 antagonist (IDP-002), and a PD-1 agonist (IDP-003) partnered with Sanofi for autoimmune indications.

InduPro is pre-revenue and operates a partnership-driven enterprise business model. The company secures strategic equity investments, R&D funding, milestone payments, and royalties through multi-program licensing deals with major pharmaceutical partners. In June 2024 it closed an $85 million Series A co-led by The Column Group and Vida Ventures. In December 2025 it announced a strategic equity investment and research collaboration with Sanofi for the bispecific PD-1 agonist program. In January 2026 it entered a global strategic collaboration with Eli Lilly covering up to three targets for total deal value of up to approximately $950 million. CEO Prakash Raman, Ph.D., joined in April 2024 from Ribon Therapeutics, with additional leadership across CSO/President Scott Lesley, Ph.D. (former Merck VP of Discovery Biologics), CMO Amanda J. Redig, M.D., Ph.D., and VPs spanning biology, chemical sciences, platform technology, biologics, operations, finance, and corporate development.

InduPro firmographics

Firmographics
Name
InduPro
Legal name
InduPro, Inc.
Website
https://induprotx.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
InduPro is a Seattle-based private biotechnology company developing proximity-based protein therapeutics that modulate cell-surface protein interactions to treat cancer and autoimmune diseases, using an AI/ML-enabled membrane interactomics platform to identify novel targets and co-target pairs.
Ownership category
akta.pro rank

InduPro industry classification

Industry
Product category
Biotechnology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Proximity-based therapeutics
  • Bispecific antibody engineering
  • Membrane interactomics platform
  • Antibody drug conjugates
  • Protein interaction modulators

Where InduPro is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Markets served

InduPro business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Collaboration & Licensing Fees: Multi-year, multi-program licensing deals with global pharma partners (Eli Lilly up to ~$950M total deal value across up to three targets; Sanofi for bispecific PD-1 agonist), typically structured with upfront payments, R&D funding, milestone payments tied to development/regulatory/commercial events, and potential royalties on commercialized products.
  2. Pharma-Funded Preclinical/IND-Enabling Research: Research funding from pharma partners (e.g., Sanofi funding preclinical and IND-enabling research activities on the PD-1 agonist program) for collaborative R&D execution.
  3. Venture Equity Financing: Pre-revenue company; primarily funded to date by venture equity ($85M Series A in 2024 plus additional equity investments from strategic partners Sanofi and Eli Lilly) used to advance pipeline and platform. Not operating revenue but primary capital inflow prior to licensing income.

Pricing tiers

ModelBillingPrice
Outcome Based/ PerformanceMulti-year contractEli Lilly collaboration: total deal value up to approximately $950 million across up to three targets, including equity investment, plus potential royalties (terms not fully disclosed)
Outcome Based/ PerformanceMulti-year contractSanofi collaboration: equity investment (undisclosed) plus research funding for preclinical/IND-enabling activities; right of first negotiation for the bispecific PD-1 agonist program

Go-to-market motion2 records

InduPro product offering

Product offering

Core offering

InduPro develops proximity-based protein therapeutics that leverage inherent and induced cell-surface protein proximity to treat cancer and autoimmune diseases. The company operates a proprietary induced-proximity drug discovery platform (MInt, ARRIS and Therapeutic Engineering) and advances a pipeline of first- and best-in-class bispecific antibody candidates, including antibody-drug conjugates (ADCs), T-cell engagers, and PD-1 modulators, which it licenses to large pharmaceutical partners via multi-year strategic collaboration deals.

Product overview

InduPro offers a single, unified induced-proximity drug discovery platform composed of three core platform modules — MInt (Membrane Interactomics), ARRIS (Proximity Modalities), and Therapeutic Engineering (TE) — that work together end-to-end: MInt catalogs inherent cell-surface protein proximity via AI/ML to identify novel targets and co-target pairs; ARRIS uses multi-specific antibody technology to design induced-proximity therapeutics against those targets; and Therapeutic Engineering provides the in-house antibody discovery, protein characterization, and optimization capabilities that translate those designs into clinical molecules. The platform fuels InduPro's pipeline of first- and best-in-class bispecific candidates, including oncology programs IDP-001 (EGFR x TAPA-E1 bispecific ADC), IDP-012 (EGFR x TAPA-E1 bispecific ADC with topoisomerase 1 inhibitor payload), IDP-004 (MET x TAPA-M1 bispecific ADC), the immuno-oncology program IDP-002 (PD1 antagonist), and the autoimmune program IDP-003 (PD1 agonist, partnered with Sanofi).

Differentiator

Problem solved

Functional benefit

Products and services

  • IDP-001 First-in-class, proximity-based bispecific antibody-drug conjugate (ADC) co-targeting EGFR and a novel tumor-associated proximity antigen (TAPA-E1) for oncology; IND filing planned for Q1 2026.
  • IDP-012 Bispecific ADC with a topoisomerase 1 inhibitor payload co-targeting EGFR and TAPA-E1 in oncology.
  • IDP-004 Bispecific ADC co-targeting MET and a novel tumor-associated proximity antigen (TAPA-M1) in oncology.
  • IDP-002 Best-in-class bispecific PD-1 antagonist (PD1 x T-Cell Antigen 1) offering superior receptor occupancy through cooperative binding, independent of VEGF; enhances T-cell signaling while limiting Treg co-activation.
  • IDP-003 Differentiated bispecific PD-1 agonist (PD1 x T-Cell Antigen 2) that recruits PD1 into the immune synapse via a non-depleting, FcR-independent mechanism; partnered with Sanofi for autoimmune and inflammatory disorders.

Companies that use InduPro

Customer profile

Ideal customer profiles1 record

InduPro technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

InduPro partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights6 records

InduPro competitors and assessment

Company assessment

Direct peers

  • HotSpot Therapeutics: Preclinical/early-clinical biotech developing induced-proximity therapeutics, including small-molecule CBL-B inhibitors, sharing InduPro's core concept of leveraging induced proximity for therapeutic effect. Comparable in stage, mechanism philosophy, and partnership-driven business model.
  • Ribon Therapeutics: Oncology biotech founded by scientists from the same academic/biopharma network as InduPro's founders and leadership. Ribon's CEO and CFO (Prakash Raman and Jeff Palmer) previously held leadership roles at Ribon before joining InduPro, making it a closely comparable oncology-focused private biotech.
  • Xilio Therapeutics: Clinical-stage immuno-oncology company developing tumor-selective bispecifics and cytokines. Comparable in stage and size, with shared leadership pedigree (Ertan Eryilmaz was previously VP of Biologics at Xilio before joining InduPro) and similar focus on selective tumor targeting.
  • Alpine Immune Sciences: Biotech developing engineered protein therapeutics for autoimmune and inflammatory diseases using directed evolution and Fc-engineering. Comparable in autoimmune/immuno-oncology focus and bispecific modality, with overlapping leadership background (Pam Holland was previously SVP of Research at Alpine).
  • Janux Therapeutics: Clinical-stage biotech developing T cell engager (TCE) bispecifics for oncology, directly overlapping with InduPro's TAPA-based TCE programs. Comparable in modality (bispecifics), indication focus (oncology), and partnership-driven strategy.
  • Cullinan Oncology: Clinical-stage oncology company developing a diversified pipeline of targeted therapies including bispecifics. Comparable as a private/early-public oncology biotech at similar stage and scale pursuing selective tumor-targeting approaches.
  • Surface Oncology: Immuno-oncology biotech developing therapeutics targeting the tumor microenvironment. Comparable in indication focus (oncology), modality (antibody-based biologics), and team pedigree (Pam Holland was previously VP of Cancer Biology at Surface).

Broad incumbents

  • Arvinas: Clinical-stage leader in targeted protein degradation (PROTACs), a related induced-proximity modality that uses bifunctional small molecules rather than antibodies. Comparable as an induced-proximity platform company but at significantly more advanced clinical stage and larger scale.
  • Kymera Therapeutics: Clinical-stage biotech developing heterobifunctional degraders (induced proximity via small molecules). Comparable platform philosophy and oncology/immunology focus, though at a more advanced clinical stage and with public-company scale and capital.
  • Genmab: Public biotech with a leading bispecific antibody platform (DuoBody) and approved assets including epcoritamab. Directly comparable in bispecific antibody technology and oncology/autoimmune focus, but operates as a broad incumbent across multiple platforms and programs rather than a single-platform specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

InduPro social profiles

Digital presence

InduPro financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InduPro leadership team

Management profile

Number of profiles

Profiles11 records

InduPro funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InduPro M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InduPro

What does InduPro do?

InduPro develops proximity-based protein therapeutics that leverage inherent and induced cell-surface protein proximity to treat cancer and autoimmune diseases. The company operates a proprietary induced-proximity drug discovery platform (MInt, ARRIS and Therapeutic Engineering) and advances a pipeline of first- and best-in-class bispecific antibody candidates, including antibody-drug conjugates (ADCs), T-cell engagers, and PD-1 modulators, which it licenses to large pharmaceutical partners via multi-year strategic collaboration deals.

Is InduPro a public or private company?

InduPro is a private company. It is classified as venture growth investor backed and is currently operating.

When was InduPro founded?

InduPro was founded in 2022. It employs 51 to 100 people.

Where is InduPro based?

InduPro is headquartered in Seattle, United States, in the North America region.

How does InduPro make money?

Three revenue lines are on record. Strategic Collaboration & Licensing Fees are the primary driver. The others are pharma-Funded Preclinical/IND-Enabling Research and venture Equity Financing.

Who are InduPro's main competitors?

Direct peers on record are HotSpot Therapeutics, Ribon Therapeutics, Xilio Therapeutics, Alpine Immune Sciences, Janux Therapeutics, Cullinan Oncology and Surface Oncology. Broad incumbents are Arvinas, Kymera Therapeutics and Genmab.

Does InduPro have an API?

No public API is recorded for InduPro.

What industry is InduPro in?

InduPro's product category is Biotechnology Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarInduPro Announces Publication in Nature Establishing Spatial Protein Proximity as a New Framework for Therapeutic DiscoveryInduPro published research in Nature establishing spatial protein proximity as a new therapeutic framework, defining Tumor-Associated Proximity Antigens (TAPAs). The study's findings underpin IDP-001, a bispecific antibody-drug conjugate now in Phase 1 clinical development for solid tumors.GeekWireInduPro raises $77M, begins first human trial of cancer drugInduPro raised $77 million in Series B funding and dosed its first patient in a Phase 1 clinical trial for IDP-001, an experimental antibody-drug conjugate targeting cancer cells. The funding round was led by The Column Group with participation from strategic partners including Sanofi and Eli Lilly, who also have a separate licensing agreement with the company. This capital will support the ongoing trial for non-small cell lung cancer and further development of InduPro's preclinical pipeline.American City Business JournalsCambridge-Seattle biotech InduPro raises $77 million Series B roundBiotech startup InduPro raised a $77 million Series B funding round to advance its oncology pipeline and support clinical trials for solid tumors. The financing coincides with the dosing of the first patient in the company's Phase 1 trial and was led by The Column Group with participation from investors including Sanofi and Eli Lilly. The funds will be used to build out clinical teams and recruit patients as the company moves its lead program toward proof of concept.American City Business JournalsSeattle biotech InduPro raises $77 million Series B roundSeattle biotech InduPro raised $77 million in a Series B round. The startup is dosing its first patient in a Phase 1 trial for a treatment aimed at lung cancer and other solid tumors.BioWorldAntibody fever in Indupro’s $77M series B, Boulevard‘s $65M launchIndupro and Boulevard Bio secured funding to advance antibody-based therapeutics, following Infinimmune's $75 million series A round. The article highlights the antibody sector's momentum, with both companies moving forward in their respective programs.FinSMEsInduPro Raises $77M in Series B FundingInduPro raised $77M in Series B financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, and others. The funds will support Phase 1 clinical development of IDP-001 for advanced non-small cell lung cancer and advance its preclinical pipeline.The Pharma LetterInduPro banks $77m series B as lead ADC enters the clinicUSA-based biotech InduPro closed a $77 million Series B financing and dosed the first patient in its Phase I study for lead cancer candidate IDP-001. The round was led by The Column Group, with participation from existing backers including Merck & Co and new investors such as Sanofi and Eli Lilly.Pulse 2.0InduPro Raises $77 Million Series B And Doses First Patient In Phase 1 Study Of IDP-001InduPro raised $77 million in Series B funding and dosed the first patient in a Phase 1 clinical trial for its lead oncology candidate, IDP-001. The financing was led by The Column Group with participation from investors including Sanofi and Eli Lilly and Company. InduPro intends to use the proceeds to advance clinical development and generate early proof-of-concept data for IDP-001.FinancialContent Business PageArticles from InduPro, Inc.InduPro, Inc. has secured $77 million in Series B financing and has begun dosing the first patient in a Phase 1 clinical study for its lead oncology program, IDP-001. This financial backing demonstrates investor confidence and sets the stage for potential advancements in cancer treatment. The company focuses on developing therapeutics for cancer and autoimmune diseases using unique membrane protein spatial relationships.BitlyInduPro raises $77M Series B for oncology drug developmentInduPro raised a $77 million Series B funding round as its lead oncology drug enters human testing. This financing highlights the continued strong interest from venture capital in cancer and autoimmune drug development.